PARTNERING
Partnering is a key enabler for our 2030 ambition and beyond.
At Servier, partnering is at the heart of our innovation strategy with bold short-term objectives as part of our long-term ambition. We are a highly committed and experienced team focused on partnerships to further innovate for patients.
We are focusing on strategic partnerships and programmatic deal-making, mainly in oncology and neurology. We aim to drive innovation by working closely with our partners to make a meaningful impact on patient lives.
In oncology, we are looking for assets from late-research to late-clinical(see our partnering brochure below for full details) :
In neurology, we aim to build a new therapeutic area in rare neurological disorders, focused on diseases with high medical need, from late-research to late-clinical (see our partnering brochure below for full details):
We also have partnering interests in cardiometabolism & venous diseases (commercial-stage assets), a range of therapeutic modalities and digital health solutions.
In addition, we are actively looking to build technological partnerships in order to accelerate the development of our therapeutic projects, notably for data analysis and artificial intelligence (see our partnering brochure below for full details).
We would welcome a discussion with interested parties.
| Asset | Target | Modality | Stage | TA | Territory |
|---|---|---|---|---|---|
| S217879 | NRF2 Activator | Small molecule | PCC | Metabolic Disease (NASH/MASH) | Worldwide |
| RHU030 | Galectin-3 | Monoclonal antibody | PCC | Immuno-Inflammatory Oncology | Worldwide |
| S95041 | CD40 | Monoclonal antibody | PCC | Immuno-Inflammatory | Worldwide |
| S95042 | OX40 | Monoclonal antibody | PCC | Immuno-Inflammatory | Worldwide |
| SYM004 | EGFR | Monoclonal antibody | Phase 2 | Oncology | Worldwide |
| SYM015 | MET | Monoclonal antibody | Phase 2a | Oncology | Worldwide |
At Servier, we have the resources and reach of a globally established pharmaceutical company combined with a long-term vision focused on developing transformative medicines for patients. Our unique value proposition enables us to build successful partnerships.
Partnering is a key enabler for our 2030 ambition and beyond.
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
Servier To Acquire a Potential Best-in-Class Precision Therapy for Acute Leukemias, from BioNova Pharmaceuticals
The start-up incubator Spartners by Servier & BioLabs, housed within our R&D Institute in Paris-Saclay, is unique in France. Operated by BioLabs, the leader in shared laboratories, the incubator is designed to accommodate over 100 scientists, within a 1,850 sqm building and located in one of the major European ecosystems.
Spartners by Servier & BioLabs offers shared or private laboratories, fully equipped with state-of-the-art facilities, enabling selected residents to work independently and benefit from the best equipment to accelerate their development.
While benefiting from the BioLabs network and services, residents also have access to the cutting edge expertise of Servier’s entire R&D chain as well as its numerous regional, national or international institutional partners. This is a tremendous opportunity for mentoring or partnering with Servier.
Do you want to join the incubator? Learn more about Spartners by Servier & BioLabs
Participate in the Golden Ticket competition for start-ups and biotechs
The Golden Ticket serves as a bridge between start-ups and the global pharmaceutical ecosystem, stimulating scientific innovation for the benefit of patients. Winning start-ups join an incubator for one year and can access all the resources needed to pave the way for new therapies, particularly in oncology and neurology.
Find out more about the Golden Ticket: accelerating start-up innovation for the benefit of patients
Since 2017, Servier has awarded an annual Golden Ticket with LabCentral in the Boston-Cambridge ecosystem. In 2024, this expanded to France with BioLabs, and in 2025, to the Nordic countries with SmiLe Venture Hub, recently ranked among “Europe’s Leading Start-up Hubs 2024”1 by the Financial Times.
Spotlight on public-private partnerships at Paris-Saclay
Boostcamp Patients: at the heart of the innovation process in oncology
Paris-Saclay: Our incubator is opening its doors!
*Oncology:
Leukemia: AML: Acute Myeloid Leukemia, ALL: Acute Lymphoblastic Leukemia, MDS: Myelodysplastic syndromes, MPN: Myeloproliferative neoplasms
GI (Gastro-intestinal) includes: PDAC: Pancreatic Ductal Adenocarcinoma, CRC: Colorectal Cancer, BTC: Biliary tract cancers, PaCa: Pancreatic Cancer, small intestine, anal, appendiceal.
Other non-core solid tumors including but not limited to: Gyn, GU, H&N, thyroid, thymoma.
Neurology:
Rare movement disorders – FA: Friedreich Ataxia; SCA: Spinocerebellar Ataxia; MSA: Multiple system Atrophy; PSP: Progressive Supranuclear Palsy; HD: Huntington Disease.
Neuromuscular disorders – ALS: Amyotrophic Lateral Sclerosis; SMA: Spinal Muscular Atrophy; DMD: Duchene Muscular Atrophy; FSHD: Fascioscapulohumeral Dystrophy; DM: Myotonic Dystrophy; MG: Myasthenia Gravis.
Refractory epilepsies – DS: Dravet Syndrome; LGS: Lennox-Gastaut Syndrome; JS: Jeavons Syndrome; WS: West Syndrome; DEE: Developmental and Epileptic Encephalopathies.
Modalities: mAb: monoclonal Antibodies ADC: Antibody Drug Conjugates, TCE: T-Cell Engager
[1] https://rankings.ft.com/incubator-accelerator-programmes-europe/ranking/europes-leading-start-up-hubs, consulted on 05/05/2025